Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 03, 2016 16:01 ET | Source: Fate Therapeutics, Inc.

Fate Therapeutics Reports Fourth Quarter and Full Year 2015 Financial Results

ProTmune™ Investigational New Drug Application for Prevention of Acute GvHD and CMV Infection Cleared by FDA in January 2016 Phase 1/2 Clinical Trial of ProTmune to Commence Enrollment in mid-2016 ...
February 25, 2016 16:01 ET | Source: Fate Therapeutics, Inc.

Fate Therapeutics to Webcast Conference Call Reporting Fourth Quarter and Full Year 2015 Financial Results on March 3, 2016

SAN DIEGO, Feb. 25, 2016 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE), a biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and...
February 21, 2016 08:01 ET | Source: Fate Therapeutics, Inc.

Fate Therapeutics to Present Preclinical Data for ProTmune™ at 2016 BMT Tandem Meetings

Poster Presentation to Highlight Anti-Tumor Properties of Ex Vivo Programmed Donor T Cells Phase 1/2 Clinical Trial of ProTmune in Mobilized Peripheral Blood HCT to Commence Enrollment in Mid-2016 ...
February 03, 2016 16:01 ET | Source: Fate Therapeutics, Inc.

Fate Therapeutics to Present at Leerink Partners 5th Annual Global Healthcare Conference

SAN DIEGO, Feb. 03, 2016 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE), a biopharmaceutical company dedicated to the development of programmed cellular immunotherapeutics for cancer...
January 26, 2016 16:36 ET | Source: Fate Therapeutics, Inc.

Fate Therapeutics Announces FDA Clearance of Investigational New Drug Application for ProTmune for Prevention of Acute GvHD and CMV Infection

SAN DIEGO, Jan. 26, 2016 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE), a biopharmaceutical company dedicated to the development of programmed cellular immunotherapeutics for cancer...
January 06, 2016 16:01 ET | Source: Fate Therapeutics, Inc.

Fate Therapeutics to Present at Biotech Showcase 2016

SAN DIEGO, Jan. 06, 2016 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE), a biopharmaceutical company dedicated to the development of programmed cellular immunotherapeutics for the...
December 07, 2015 06:00 ET | Source: Fate Therapeutics, Inc.

Fate Therapeutics Provides Update on Adoptive Immunotherapy Programs for Hematopoietic Cell Transplantation

Supportive Interim Data from ProHema® PUMA Study Demonstrate the Therapeutic Potential of Programmed Donor Cells Clinical Development Strategy to Focus on Prevention of Life-Threatening...
December 03, 2015 08:01 ET | Source: Fate Therapeutics, Inc.

Fate Therapeutics to Present at Oppenheimer & Co. 26th Annual Healthcare Conference

SAN DIEGO, Dec. 3, 2015 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE), a biopharmaceutical company dedicated to the development of programmed cellular immunotherapeutics for the treatment...
November 05, 2015 09:05 ET | Source: Fate Therapeutics, Inc.

Fate Therapeutics to Present Strategy for the Development of Off-the-Shelf Cancer Immunotherapies at ASH 2015

SAN DIEGO, Nov. 5, 2015 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE), a biopharmaceutical company dedicated to the development of programmed cellular immunotherapeutics for the treatment...
November 05, 2015 09:01 ET | Source: Fate Therapeutics, Inc.

Fate Therapeutics to Present Preclinical Data for ProTmune(TM) at ASH 2015 Annual Meeting

First-in-Human Clinical Trial to Prevent Acute Graft-versus-Host Disease and Severe Infections Planned for 2016 Poster Presentations to Highlight Preclinical Findings and Potential Therapeutic and...